Nuvilex Investors Wa
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
August 28, 2013 08:30 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Drug Makers Could So
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
August 22, 2013 08:30 ET | Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Flowering Corn Lily
Photo Release -- Biopharmaceutical Company Seeks New Sources of Corn Lily
June 22, 2011 10:00 ET | Infinity Pharmaceuticals, Inc.
SALT LAKE CITY and BOISE, Idaho, June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, is seeking new sources of a plant commonly known as...
Infinity Pharmaceuticals, Inc. Logo
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
June 22, 2011 08:00 ET | Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...
Infinity Pharmaceuticals, Inc. Logo
Infinity Reports First Quarter 2011 Financial Results
May 10, 2011 16:00 ET | Infinity Pharmaceuticals, Inc.
— Reaffirms 2011 Financial Guidance and Provides Additional Details — —    Anticipates Completion of Patient Enrollment in Phase 2 Trial of IPI-926 in Pancreatic Cancer...
Infinity Pharmaceuticals, Inc. Logo
Infinity Reports New Preclinical Data for IPI-926 at AACR Supporting Development in Chondrosarcoma
April 03, 2011 13:36 ET | Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results for its novel Smoothened antagonist, IPI-926, in a preclinical...
Infinity Pharmaceuticals, Inc. Logo
Infinity Provides Company Update and Reports Fourth Quarter and Full-Year 2010 Financial Results
March 15, 2011 16:00 ET | Infinity Pharmaceuticals, Inc.
IPI-926 Advancing in Two Phase 2 Trials, Underscoring Pipeline Momentum Cash Runway Into 2014 Enables Advancement of Product Candidates to Key Inflection Points Company Changes Accounting...